Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination

Martin de la Presa; Amit Govil; Winston D. Chamberlain; Edward J. Holland

doi:10.1097/ICO.0000000000002914

Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination

Martin de la Presa, Amit Govil, Winston D. Chamberlain, Edward J. Holland

Ophthalmology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Purpose: The purpose of this study was to report a case of acute corneal epithelial rejection of living-related conjunctival limbal allograft (LR-CLAL) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Observations: A 27-year-old woman developed acute epithelial rejection of LR-CLAL 2 weeks after receiving the SARS-CoV-2 vaccine. She received the LR-CLAL transplant 4 years and 7 months previously and had a stable clinical course with no history of rejection. She had an ABO blood group and human leukocyte antigen compatible donor, no systemic comorbidities, and no rejection risk factors. Conclusions: The novel SARS-CoV-2 vaccine upregulates the immune system to produce an adaptive immune response. The SARS-CoV-2 vaccine may potentially be associated with increased risk of rejection in those with ocular surface transplants.

Original language	English (US)
Pages (from-to)	252-253
Number of pages	2
Journal	Cornea
Volume	41
Issue number	2
DOIs	https://doi.org/10.1097/ICO.0000000000002914
State	Published - Feb 1 2022

Keywords

COVID-19
Rejection
SARS-CoV-2
Transplant
Vaccine

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/ICO.0000000000002914

Cite this

@article{539bee68fa56440fa26815f24358e05f,

title = "Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination",

abstract = "Purpose: The purpose of this study was to report a case of acute corneal epithelial rejection of living-related conjunctival limbal allograft (LR-CLAL) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Observations: A 27-year-old woman developed acute epithelial rejection of LR-CLAL 2 weeks after receiving the SARS-CoV-2 vaccine. She received the LR-CLAL transplant 4 years and 7 months previously and had a stable clinical course with no history of rejection. She had an ABO blood group and human leukocyte antigen compatible donor, no systemic comorbidities, and no rejection risk factors. Conclusions: The novel SARS-CoV-2 vaccine upregulates the immune system to produce an adaptive immune response. The SARS-CoV-2 vaccine may potentially be associated with increased risk of rejection in those with ocular surface transplants.",

keywords = "COVID-19, Rejection, SARS-CoV-2, Transplant, Vaccine",

author = "{de la Presa}, Martin and Amit Govil and Chamberlain, {Winston D.} and Holland, {Edward J.}",

year = "2022",

month = feb,

day = "1",

doi = "10.1097/ICO.0000000000002914",

language = "English (US)",

volume = "41",

pages = "252--253",

journal = "Cornea",

issn = "0277-3740",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination

AU - de la Presa, Martin

AU - Govil, Amit

AU - Chamberlain, Winston D.

AU - Holland, Edward J.

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Purpose: The purpose of this study was to report a case of acute corneal epithelial rejection of living-related conjunctival limbal allograft (LR-CLAL) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Observations: A 27-year-old woman developed acute epithelial rejection of LR-CLAL 2 weeks after receiving the SARS-CoV-2 vaccine. She received the LR-CLAL transplant 4 years and 7 months previously and had a stable clinical course with no history of rejection. She had an ABO blood group and human leukocyte antigen compatible donor, no systemic comorbidities, and no rejection risk factors. Conclusions: The novel SARS-CoV-2 vaccine upregulates the immune system to produce an adaptive immune response. The SARS-CoV-2 vaccine may potentially be associated with increased risk of rejection in those with ocular surface transplants.

AB - Purpose: The purpose of this study was to report a case of acute corneal epithelial rejection of living-related conjunctival limbal allograft (LR-CLAL) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Observations: A 27-year-old woman developed acute epithelial rejection of LR-CLAL 2 weeks after receiving the SARS-CoV-2 vaccine. She received the LR-CLAL transplant 4 years and 7 months previously and had a stable clinical course with no history of rejection. She had an ABO blood group and human leukocyte antigen compatible donor, no systemic comorbidities, and no rejection risk factors. Conclusions: The novel SARS-CoV-2 vaccine upregulates the immune system to produce an adaptive immune response. The SARS-CoV-2 vaccine may potentially be associated with increased risk of rejection in those with ocular surface transplants.

KW - COVID-19

KW - Rejection

KW - SARS-CoV-2

KW - Transplant

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85123651700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123651700&partnerID=8YFLogxK

U2 - 10.1097/ICO.0000000000002914

DO - 10.1097/ICO.0000000000002914

M3 - Article

C2 - 34743101

AN - SCOPUS:85123651700

SN - 0277-3740

VL - 41

SP - 252

EP - 253

JO - Cornea

JF - Cornea

IS - 2

ER -

Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this